BLVIS A Blue Vision A

Pharma Equity Group A/S’ agreement with Danske Bank as liquidity provider will terminate on 1 January 2026

Pharma Equity Group A/S’ agreement with Danske Bank as liquidity provider will terminate on 1 January 2026

Pharma Equity Group A/S’ agreement with Danske Bank as liquidity provider will terminate on 1 January 2026

3 December 2025

Company Announcement no. 14



Pharma Equity Group A/S (“PEG”) announces that the Company’s agreement with Danske Bank as liquidity provider will terminate with effect from 1 January 2026.

In connection with the termination of the agreement, the Company has evaluated its current market strategy. It is the management's assessment that, at this stage, greater value is created for shareholders by allocating resources to direct and targeted communication and Investor Relations activities rather than a contracted market maker arrangement.

Consequently, PEG has chosen not to enter into an agreement with a new liquidity provider upon the expiration of the current agreement.

The last trading day with Danske Bank acting as liquidity provider is 31 December 2025.

The Company notes that this change may technically affect the liquidity of PEG’s share, including the bid-ask spread, as there will no longer be an external party obligated to provide bid and ask quotes from the turn of the year.

This decision does not alter PEG’s overall strategic direction regarding business development.

Further information:

Christian Vinding Thomsen, Chairman of the Board, Tel.

Christian Tange, CEO, Tel.

About Pharma Equity Group A/S

Pharma Equity Group (PEG) is a dynamic investment and development company within Life Science and is listed on Nasdaq Copenhagen. PEG identifies, acquires and develops innovation projects within pharmaceuticals, MedTech and other medical devices with a particular focus on early-stage innovation projects, especially those originating from

Scandinavian research institutions. Through strategic capital allocation, strong governance with a dedicated investment committee, and an extensive industry network, PEG works to convert groundbreaking ideas into impactful healthcare solutions and products. The Company aims to build a balanced portfolio that creates continuous value and supports long-term growth—for the benefit of patients, healthcare systems and investors.

Attachment



EN
03/12/2025

Underlying

BLVIS ABlue Vision A

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Blue Vision A

 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Finans Kalender for 2026

Finans Kalender for 2026 3. februar 2026 Pressemeddelelse  Pharma Equity GroupFinans Kalender for 2026 4. martsFrist for aktionærforslag - Ordinær generalforsamling 18. marts Årsrapport 2025 16. aprilOrdinær generalforsamling 14. augustDelårsrapport – for halvåret, der sluttede 30. juni 2026  Kontaktperson – Investor Relations På selskabets hjemmeside kan yderligere information og alle offentliggjorte meddelelser findes. Henvendelser vedrørende Investor Relations og aktiemarkedet kan rettes til: Christian Henrik Tange, CEO, Telefon: E-mail: . Om Pharma Equity Group A/S Pharma Equity...

February 3, 2026 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

2026 Financial Calendar

2026 Financial Calendar 3 February 2026 News Release  Pharma Equity Group2026 Financial Calendar ​March 4Deadline for shareholder proposals - Annual General meeting​ ​March 18 ​Annual Report 2025​ April 16Annual General Meeting​ August 14Interim Report – for the six-month period ended June 30. 2026​  ​Contact person – Investor Relations On the Company’s website further information and all published announcements can be found. Inquiries regarding relations with investors and the stock market can be directed to: Christian Henrik Tange, CEO, Phone: E-mail: . About Pharma Equity Group A/...

February 3, 2026 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Pharma Equity Group – Strategisk opdatering og justering af forventnin...

Pharma Equity Group – Strategisk opdatering og justering af forventninger Pharma Equity Group – Strategisk opdatering og justering af forventninger København, 29. december 2025 Selskabsmeddelelse nr. 16 Pharma Equity Group A/S (”PEG” eller ”Selskabet”) offentliggør hermed en strategisk opdatering vedrørende selskabets omsætningsforventninger, udviklingen i pipelineprojekterne RNX-051 og RNX-011 samt den overordnede kommercialiseringsstrategi. Justering af tidligere kommunikerede forventninger Selskabet konstaterer, at de omsætnings- og resultatforventninger for indeværende regnskabsår,...

December 29, 2025 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Pharma Equity Group – Strategic update and adjustment of expectations

Pharma Equity Group – Strategic update and adjustment of expectations Pharma Equity Group – Strategic update and adjustment of expectations Copenhagen, 29 December 2025 Company Announcement no. 16 Pharma Equity Group A/S (“PEG” or the “Company”) hereby provides a strategic update regarding the Company’s revenue expectations, the development of the pipeline projects RNX-051 and RNX-011, and the overall commercialisation strategy. Adjustment of previously communicated expectations The Company notes that the revenue and earnings expectations for the current financial year, as previously c...

December 29, 2025 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Pharma Equity Group eksekverer på selskabets nye strategi: Indgår hens...

Pharma Equity Group eksekverer på selskabets nye strategi: Indgår hensigtserklæring om opkøb af MedTech-virksomheden Otiom A/S Pharma Equity Group eksekverer på selskabets nye strategi: Indgår hensigtserklæring om opkøb af MedTech-virksomheden Otiom A/S København, 10. december 2025 Selskabsmeddelelse nr. 15 Pharma Equity Group A/S ("PEG") meddeler i dag, at selskabet har underskrevet en hensigtserklæring (Letter of Intent) om erhvervelse af hele aktiekapitalen eller en majoritetsandel i Otiom A/S. Transaktionen markerer første konkrete skridt i PEG’s udvidede strategi om at blive en mark...

December 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch